(Q45723228)

15 December 2017

A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. (English)

1 reference

15 December 2017

1 reference

Rebeca Geffin

1

1 reference

15 December 2017

Cecelia Hutto

series ordinal

2

1 reference

15 December 2017

Carole Andrew

series ordinal

3

1 reference

15 December 2017

Gwendolyn B Scott

series ordinal

4

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

15 December 2017

9

1 reference

inferred from page(s)

published in

Virology

1 reference

15 December 2017

310

1 reference

15 December 2017

2

1 reference

15 December 2017

207-215

1 reference

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

15 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Disquisitions of Original Antigenic Sin. I. Evidence in man

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

A hospital-based prospective study of perinatal infection with human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Cellular tropisms and co-receptor usage of HIV-1 isolates from vertically infected children with neurological abnormalities and rapid disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2803%2900137-5

7 January 2021

10.1016/S0042-6822(03)00137-5

Identifiers

DOI

1 reference

15 December 2017

1 reference